Background Anaemia associated with cancer and cancer therapy is an important clinical
factor in the treatment of malignant diseases. Therapeutic alternatives are recombinant …

model of heart failure induced by myocardial infarction, anemia was linked to activation of
the TNF-/Fas signaling pathway. 34 The number of bone marrow progenitor cells and the …

Background Although vascular endothelial growth factor (VEGF) is a primary mediator of
retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal …

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by
preventing apoptosis. However, EPO administration can also raise the hemoglobin …

Venous thromboembolism (VTE) is a major health problem in patients with cancer. Cancer
augments thrombosis and causes cancer-associated thrombosis (CAT) and vice versa …

Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates
hematopoiesis in the bone marrow. However, recent studies have also shown important …

Abnormal tissue factor (TF) expression has been demonstrated on blood monocytes and
circulating endothelial cells in humans with sickle cell anemia. We have now studied sickle …

Erythropoietin (EPO) is a hormone known to stimulate hematopoiesis. However, recent
research suggests additional properties of EPO, such as protection against …

Recent advances in immunology enabled the characterization of several signal transmitting
pathways responsible for proper cytokine and chemokine signaling. Among them, Janus …

Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells.
As recently reviewed by Smith et al.[Cardiovasc. Res. 59 (2003) 538–548], Epo can also act …